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Data regarding the effects of oral contraceptive use on women’s risk of melanoma have been difﬁcult to resolve. We
undertook a pooled analysis of all case–control studies of melanoma in women completed as of July 1994 for which
electronic data were available on oral contraceptive use along with other melanoma risk factors such as hair colour, sun
sensitivity, family history of melanoma and sun exposure. Using the original data from each investigation (a total of 2391 cases
and 3199 controls), we combined the study-speciﬁc odds ratios and standard errors to obtain a pooled estimate that
incorporates inter-study heterogeneity. Overall, we observed no excess risk associated with oral contraceptive use for 1 year
or longer compared to never use or use for less than 1 year (pooled odds ratio (pOR)=0.86; 95% CI=0.74–1.01), and there
was no evidence of heterogeneity between studies. We found no relation between melanoma incidence and duration of oral
contraceptive use, age began, year of use, years since ﬁrst use or last use, or speciﬁcally current oral contraceptive use. In
aggregate, our ﬁndings do not suggest a major role of oral contraceptive use on women’s risk of melanoma.
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Until about age 45 years incidence rates of melanoma in women
exceed those in men, after which rates markedly rise in men but level
off slightly in women (Armstrong and English, 1996). Additionally,
women with a history of melanoma are at greater risk of breast cancer
and vice versa (Schoenberg and Christine, 1980). These descriptive
ﬁndings raise the possibility that female sex steroids may be involved
in the aetiology of melanoma in women. Several epidemiologic
studies have speciﬁcally addressed the possible role of oral contracep-
tive use in the occurrence of melanoma, but with conﬂicting results.
Over 20 years ago, results from three cohort studies suggested a high-
er incidence of melanoma among women who had used oral
contraceptives compared to women who had never used them (Beral
et al, 1977; Kay, 1981; Ramcharan et al, 1981). Relative risk estimates
ranged from 1.4 to 3.5. However, these ﬁndings were based on a rela-
tively small number of cases, and another cohort study found no
excess risk (Adam et al, 1981). Subsequent case–control and cohort
studies (Bain et al, 1982; Holly et al, 1983, 1995; Holman et al, 1984;
Helmrich et al, 1984; Beral et al, 1984; Gallagher et al, 1985; Green
and Bain, 1985; Østerlind et al, 1988; Zanetti et al, 1990; Hannaford
et al, 1991; Le et al, 1992; Palmer et al, 1992; Westerdahl et al, 1996;
Gefeller et al, 1998; Smith et al, 1998; Feskanich et al, 1999) provided
little evidence of an overall excess risk among ever users compared to
never users, but a possible increase among long-term users
(summarised in (Prentice and Thomas, 1987)). More recently, data
from the Nurse’s Health Studies indicated a risk of melanoma related
to duration of oral contraceptive use, but only among current users
(Feskanich et al, 1999). Use of different exposure categories makes
summarising the published literature problematic, particularly for
duration of use. Moreover, a number of studies collected information
on oral contraceptive use but never reported the results. To clarify
whether use of oral contraceptive relates to melanoma risk in women,
we undertook a collaborative, pooled analysis using the original data
of completed epidemiologic studies, including those for which ﬁnd-
ings on oral contraceptive use had not been published
MATERIALS AND METHODS
Selection of studies for analysis
We identiﬁed epidemiologic studies of melanoma completed as of
July 1, 1994. In addition to an extensive literature review, we
contacted an established consortium of melanoma investigators
(Bliss et al, 1995; Ford et al, 1995). One criticism of the early
studies was that they lacked information on potentially confound-
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ascertained data on major melanoma risk factors including
pigmentary characteristics and sunlight exposure. We further
restricted our analysis to studies that involved a personal interview
because questions designed for postal surveys might be phrased
differently or be less complex. We also excluded studies limited
to hospitalised cases since these cases might be biased because of
over-representation of advanced lesions. Finally, we analysed only
studies that included at least 100 women cases and 100 women
controls as smaller studies would require a similar analytic effort,
but contribute little to the overall analysis.
Eleven case–control studies met the analysis criteria (Beral et
al, 1984; Holman et al, 1984; Gallagher et al, 1985; Green and
Bain, 1985; Østerlind et al, 1988; Swerdlow et al, 1986; Elwood
et al, 1990; Zanetti et al, 1990; Kirkpatrick et al, 1994; Holly et
al, 1995; Langholz et al, 2000) and data were available for all
but one of these (Beral et al, 1984). The investigators from all
of the remaining studies agreed to take part. Six studies had
been included in a prior pooled analysis of pigmentary charac-
teristics and freckling (Bliss et al, 1995) and ﬁve in a pooled
analysis of family history of melanoma (Ford et al, 1995). Four
studies had not previously published or presented results on oral
contraceptive use (Swerdlow et al, 1986; Elwood et al, 1990;
Kirkpatrick et al, 1994; Langholz et al, 2000). Table 1 provides
a summary of the number of cases and controls, study locations,
age ranges, study period, and method of selection of cases and
controls. In each study, cases comprised histologically conﬁrmed,
incident melanoma and about half the studies veriﬁed diagnoses
by a standardised histopathology review. Four studies excluded
lentigo maligna melanomas; one study further excluded nodular
melanomas and another was limited to superﬁcial spreading and
nodular melanomas. Only one study identiﬁed cases from
dermatology clinics; all the others used central cancer registries
or pathology laboratories for a speciﬁc geographic region. All
studies matched on age either by pairs or by stratum. Many
studies additionally matched on area of residence. Controls were
sampled from population lists, random digit dialing, neighbour-
hood sampling, or clinic and hospitalised patients. Nine studies
conducted interviews in-person and one completed interviews by
telephone.
We requested a complete data set of all variables excluding
personal identiﬁers. A copy of the original questionnaire and
coding documentation accompanied each study. Materials from
the Italian (Zanetti et al, 1990) and Danish (Østerlind et al,
1988) studies required English translation. Upon receipt, we trans-
ferred data sets containing information on individual study
subjects onto an IBM RS600 system and converted them into
SAS data ﬁles. To ensure accuracy of the received and coded data,
we performed range checks and other descriptive statistics. We
compared our counts with the published data and with unpub-
lished data from previous combined analyses or those provided
by the original study investigators. We reported summary statistics
back to the individual study investigators for conﬁrmation and
resolution of any discrepancies.
Study variables
We developed a common set of exposure variables by reviewing
each study’s questionnaire. Nine of 10 studies asked women if they
ever used oral contraceptives. One study (Langholz et al, 2000)
asked women about their contraceptive use between pregnancies.
For this study, we constructed an ‘ever use’ variable by examining
use in each phase of life. Two studies (Zanetti et al, 1990; Kirkpa-
trick et al, 1994) asked women whether they used oral
contraceptives for a speciﬁed length of time, e.g., at least 6 months
or for 90 days. For uniformity, we deﬁned ‘ever use’ of oral contra-
ceptives as 1 or more years of use and the referent category as no
use or less than 1 year of use.
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number of years or months of use. For some studies, we needed
to compute the number of months or years using dates started
and stopped for each episode of oral contraceptive use. We used
questions on age began and ended or year began and ended to
calculate age at ﬁrst use, year of ﬁrst use, number of years since
ﬁrst use, and number of years since last use of oral contraceptives.
Statistical methods
We used a two-stage method to analyse the pooled case–control
data (Stukel et al, 2001). In the ﬁrst stage, each study was analysed
according to the original design (pair matched or frequency
matched) using uniformly deﬁned exposure variables across all
studies but study-speciﬁc confounders. For pair-matched studies,
we used conditional logistic regression to derive odds ratios
(OR) and 95% conﬁdence intervals. For studies that frequency
matched on age, we used unconditional logistic regression and
controlled for age, grouped as 535, 35–44, 545 years.
The study-speciﬁc adjusted odds ratios and standard errors were
combined in a second-stage linear mixed-effects model that incor-
porated random study effects (inter-study heterogeneity) to
produce a pooled exposure odds ratio and standard error. The esti-
mator of the pooled exposure effect is a weighted average of the
individual study estimators, weighted by the inverse marginal
variances; the marginal variance is the sum of the individual
study-speciﬁc variances and the variance of the random study
effects. To assess inter-study variability, we examined the study-
speciﬁc ORs and tested for heterogeneity using a w
2 test. In the
absence of heterogeneity, we weighted by the inverse of the
study-speciﬁc variances alone since the variance of the random
study effects was treated as negligible. Further details as well as
comparisons of this model with a joint logistic regression are given
in Stukel et al (2001). Additionally, we examined study factors that
could contribute to heterogeneity in the odds ratios in subgroup
analyses based on: (1) type of control group (e.g. restricting to
population-based studies), (2) type of interview (i.e., exclusion of
the Kirkpatrick et al (1994) study that used a telephone interview)
and (3) questionnaire format (i.e., exclusion of the Langholz et al
(2000) study that asked contraceptive history between pregnancies).
Our primary exposures of interest were ‘ever use’ of oral contra-
ceptives of 1 year or greater duration, duration of use (55, 5–9,
510 years of use), age began (525, 25–29, 30–34, 535 years),
years since ﬁrst use (410, 11–15, 415 years), years since last
use (52 or current use, 2–5, 45 years), and year of ﬁrst use
(before 1970 vs 1970 or after). For each, the reference category
was ‘never use’ of oral contraceptives or use of less than 1 year.
We also examined whether the effects of duration of use (grouped
as 55o r55 years) were modiﬁed by number of years since ﬁrst
use (510 or 510 years). Due to small strata in this analysis, we
broke the matched pairs and adjusted for age using the same cate-
gories used in the frequency matched studies. To further examine
the risk of melanoma among current, long-term users, we
combined the data from all studies on women less than 50 years
of age. We then analysed current use, deﬁned as use in the 2 years
prior to diagnosis or interview date, among those with 10 or more
years of use compared to our non-user reference group. Stratifying
on ‘study’, we obtained conditional maximum likelihood estimates
both for the individual studies and for all studies combined
(Breslow and Day, 1980)
To the extent possible, we uniformly deﬁned and coded multiple
potentially confounding factors (summarised in Appendix 1). We
used the classiﬁcation scheme developed for earlier pooled analyses
for eye colour, hair colour and family history of melanoma (Bliss et
al, 1995; Ford et al, 1995). We grouped skin reaction to the sun
into three categories (i.e., never burn, burn then tan, or always
burn). Level of education was categorised into grade/high school,
college, or graduate school, except in two studies (Østerlind et
al, 1988; Kirkpatrick et al, 1994) that included a category for tech-
nical school. The deﬁnition and method for assessing nevi differed
across studies. All but one study included a nevus count on the
arms; the study done by Holly et al (1983) collected whole body
count of nevi greater than 5 mm. For all studies, we grouped
number of nevi as none, 1–4, 5–9, and 510 nevi. Questions
relating to sun exposure history considerably varied across studies.
Therefore, we included the UV light-related factors most strongly
related to melanoma risk within each study. These included history
of sunburns, sun exposure, and migration to Australia (see Appen-
dix 1).
To assess the impact of potentially confounding factors, we
examined the per cent change in the age-adjusted ORs with the
addition of the factor for each individual study separately as well
as on the combined, pooled estimates. Using our two-staged
approach, by ﬁrst analysing each study separately, we were able
to assess the potentially confounding effects of variables that were
not included in all studies or that were measured differently (e.g.,
sun exposure) (Stukel et al, 2001). For example, to assess the
impact of adjustment for nevi, we adjusted for both age and nevi
in the eight studies that collected nevi information, and age alone
in studies without nevi data. We did not ﬁnd that addition of any
potential confounder altered the pooled estimates by more 10%.
Therefore, we adjusted our ﬁnal estimates for only age.
Our analysis of oral contraceptives was conducted for all mela-
nomas combined and for superﬁcial spreading melanoma (SSM)
speciﬁcally. There were too few cases of nodular melanomas or
lentigo maligna melanomas to perform detailed analyses of these
histologic types.
RESULTS
A total of 2391 cases and 3199 controls were included in the analy-
sis for the 10 case–control studies (Table 1). The prevalence of
oral contraceptive use among controls (for 1 year or greater)
ranged from 15% in the study from Italy (Zanetti et al, 1990) to
63% in the study from Northern California (Holly et al, 1985)
(Table 2). Among controls who used oral contraceptives for at least
1 year, the median duration of use ranged from 3 to 5 years,
median age at ﬁrst use, 21 to 26 years, and median years since ﬁrst
use, 9 to 17 years (Table 2). The median year of ﬁrst use among
controls ranged from 1967 to 1977 across studies (Table 2).
The overall pooled odds ratio for ‘ever use’ of oral contraceptive
and melanoma was close to unity (pooled odds ratio (pOR)=0.86;
95% CI=0.74–1.01) (Figure 1). The ORs for ever use of oral
contraceptives were not signiﬁcantly elevated in any study, and
for many studies were less than one. There was no statistically
signiﬁcant heterogeneity across studies (w
2=7.15, P=0.62). The
ﬁndings generally were similar for superﬁcial spreading melanoma
(pOR=0.93, 95% CI=0.79–1.10, with no statistically signiﬁcant
heterogeneity (w
2=11.82, P=0.22). The risk of melanoma was unre-
lated to duration of use, age began, time since ﬁrst and last use of
oral contraceptives, or year of ﬁrst use (Table 3). Again, we found
comparable results when we restricted the analysis to SSM (Table
3). We detected evidence of statistically signiﬁcant inter-study
heterogeneity in only two strata:410 years since ﬁrst use, and
2–5 years since last use (Table 3), and for these estimates used
the random effects model. As mentioned, adjustment for poten-
tially confounding factors (e.g., eye colour, hair colour, level of
education, family history of melanoma, number of nevi, skin type
and sun exposure history) did not change any of the pORs by
more than 10%.
When we evaluated the effects of duration of use stratiﬁed by
time since ﬁrst use, we found that the pORs, for the most part,
approached unity (Table 4). However, in ﬁve studies, the ORs were
elevated among women who used oral contraceptives for 5 or more
years and who began using them within the past 10 years. In three
studies the ORs for these women were close to one and in one
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(7), 1085–1092study the OR was below one (Table 4 ). The overall pOR was 1.40
(95% CI=0.80–2.46). Excluding one study that used a differently
formatted questionnaire (Langholz et al, 2000), the pOR for this
stratum was 1.96 (95% CI=1.02–3.76). While the individual study
ORs appeared to vary, there was no statistical heterogeneity in the
ORs across studies (w
2=9.61, P=0.29). Again, none of these odds
ratios changed by more than 10% with the additional potentially
confounding factors. Results were similar for SSM (data not
shown).
To examine the effects of long-term oral contraceptive use
among current oral contraceptive users, we pooled data on women
younger than age 50 years. In total, there were 61 cases and 87
controls who were current oral contraceptive users with 10 or more
years of use. Combining data into a single conditional logistic
model and adjusting for ‘study’, the odds ratio among current,
long-term users compared to non-users was 0.91 (95% CI=0.62–
1.32). There was no evidence of inter-study heterogeneity (P value
for heterogeneity=0.82).
DISCUSSION
In our combined re-analysis of 10 case–control studies of melano-
ma in women, we found no overall association between use of oral
contraceptives and melanoma risk. Studies included in our analysis
represent the largest case–control studies of women completed by
1994 that personally interviewed women about their use of oral
contraceptives along with other melanoma risk factors. By applying
strict selection criteria, we attempted to minimise inter-study
heterogeneity in results that could arise from design characteristics.
Still, some aspects varied between studies, such as method of case
or control selection (i.e., clinic vs population-based), type of inter-
view (in-person vs telephone) and questionnaire format (i.e.,
simple to complex). However, we observed negligible difference
in our ﬁndings according to these factors.
There are reasons for suspecting that sex-steroids might affect
women’s risk of melanoma. Melanomas rarely occur before the
age of 15 years, but incidence rises with age thereafter (Armstrong
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Table 2 Control group prevalence of oral contraceptive use in each study
Ever use
a Duration of use Age at ﬁrst use Years since ﬁrst use Current use
b Year of ﬁrst use
Study (%) Median (range) Median (range)
c Median (range)
c (%)
c Median (range)
Elwood et al, 1990 37 5 (1, 21) — — — —
c
Gallagher et al, 1985 43 5 (1, 21) 24 (14, 45) 14 (1, 25) 9 1967 (1956, 1980)
Green and Bain, 1985 40 4 (1, 18) 23 (15, 39) 12 (1, 25) 11 1968 (1955, 1979)
Holly et al, 1985 63 4 (1, 20) 21 (14, 46) 17 (0, 33) 10 1968 (1952, 1984)
Holman et al, 1984 41 4 (1, 15) 22 (12, 44) 10 (1, 21) 18 1970 (1959, 1980)
Kirkpatrick et al, 1994 35 5 (1, 16) 25 (20, 42) 16 (5, 31) 6 1967 (1953, 1977)
Langholz et al, 2000 38 5 (1, 24) 23 (13, 50) 14 (4, 26) 5 1967 (1953, 1977)
Østerlind et al, 1988 38 5 (1, 20) 24 (14, 50) 15 (1, 27) 8 1970 (1958, 1984)
Swerdlow et al, 1986 37 3 (1, 20) 24 (16, 51) 12 (0, 22) 8 1971 (1961, 1983)
Zanetti et al, 1990 15 3 (1, 10) 26 (18, 47) 9 (1, 36) 4 1977 (1969, 1984)
aEver use is deﬁned as oral contraceptive use for one year or longer.
bCurrent use is deﬁned as less than 2 years since last use.
cData not
available.
Elwood 49/51 90/87
Gallagher 150/155 211/206
Green 41/45 72/69
Holly 277/586 175/348
Holman 122/113 153/164
Kirkpatrick 51/51 74/93
Langholz 100/138 241/228
Osterlind 96/201 182/335
Swerdlow 36/42 74/72
Zanetti 15/29 151/165
All Studies Pooled 687/1411 1423/1767
0.90 (0.48 – 1.70)
0.92 (0.64 – 1.32)
0.78 (0.39 – 1.56)
0.94 (0.73 – 1.19)
1.29 (0.81 – 2.06)
0.65 (0.36 – 1.19)
0.66 (0.47 – 0.92)
0.89 (0.62 – 1.26)
0.73 (0.35 – 1.52)
0.78 (0.37 – 1.64)
0.86 (0.74 – 1.01)
Study Oral contraceptive use Odds ratios for melanoma and oral contraceptive use
Users Non-users
Cases/Controls Cases/Controls OR (95% CI)* OR (95% CI)
0.0 0.5 1.0 1.5 2.0 2.5
Figure 1 Study speciﬁc and pooled odds ratios (95% conﬁdence intervals) for melanoma in women in relation to use of oral contraceptives. User of oral
contraceptives deﬁned as 1 or more years of oral contraceptive use and non-user as never use or less than one year of use. The individual study odds ratios
are shown as a solid box and the pooled estimate as an open diamond. The size of the box is inversely proportional to the standard deviation for the odds
ratio. Lines show the 95% conﬁdence intervals.
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than men prior to age 45 years, and after age 50 years, the rate
of increase with age slows in women but rises steeply in men
(Armstrong and English, 1996). The shape of the age incidence
curve for melanoma resembles that of breast cancer and suggests a
possible role of sex steroids and reproductive factors in the patho-
genesis of both of these tumours. Indeed, women with a history of
breast cancer appear to be at increased risk of melanoma and vice
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Table 3 Risk of melanoma in relation to duration, age began, time since ﬁrst and last use, and year of ﬁrst use of oral
contraceptives
All histologies Superﬁcial spreading melanoma
Number of Number of Pooled odds ratio
a Number of Pooled odds raio
a
Oral contraceptive use controls cases (95% CI) cases (95% CI)
Duration of use (years)
Non-user
b 1767 1423 1.00 (reference) 939 1.00 (reference)
55 707 450 0.83 (0.68–1.01) 333 0.87 (0.71–1.07)
5–9 452 317 0.95 (0.75–1.20) 246 1.02 (0.81–1.30)
510 252 170 0.95 (0.71–1.26) 145 1.10 (0.83–1.46)
Age began (years)
Non-user
b 1680 1333 1.00 (reference) 860 1.00 (reference)
525 831 548 0.88 (0.70–1.10) 425 0.91 (0.72–1.15)
25–29 219 144 0.84 (0.61–1.15) 105 0.91 (0.66–1.27)
30–34 153 82 0.67 (0.46–0.98) 63 0.91 (0.62–1.33)
535 151 110 1.02 (0.74–1.42) 79 1.17 (0.81–1.68)
Years since ﬁrst use
Non-user
b 1680 1333 1.00 (reference) 860 1.00 (reference)
410 310 240 0.89 (0.52–1.53)
c 177 0.86 (0.45–1.65)
c
11–15 434 315 0.99 (0.77–1.26) 244 1.04 (0.82–1.33)
415 610 329 0.78 (0.63–0.98) 251 0.88 (0.69–1.10)
Years since last use
Non-user
b 1680 1333 1.00 (reference) 860 1.00 (reference)
Current (52) 267 182 0.94 (0.68–1.30) 142 1.05 (0.75–1.46)
2–5 217 176 0.94 (0.52–1.68) 134 0.91 (0.47–1.77)
c
45 848 517 0.79 (0.66–0.96) 389 0.88 (0.72–1.07)
Year of ﬁrst use
Non-user
b 1680 1333 1.00 (reference) 860 1.00 (reference)
Before 1970 773 537 0.88 (0.73–1.07) 410 0.97 (0.79–1.20)
1970 or after 580 346 0.75 (0.58–0.97) 262 0.82 (0.62–1.07)
aAge-adjusted.
bNon-user deﬁned as never use or less than one year of use.
cw
2 heterogeneity, P50.05. Estimate based on a random
effects model (see text).
Table 4 Study-speciﬁc and pooled odds ratios (95% conﬁdence intervals)
a for duration of oral contraceptive use by
years since ﬁrst use
Duration of use
55 years 55 years
Years since ﬁrst use Years since ﬁrst use
Study 510 years 510 years 510 years 510 years
Gallagher 1.50 (0.53–4.21) 0.95 (0.52–1.76) 6.00 (0.72–49.84) 0.62 (0.36–1.06)
Green 2.00 (0.37–10.92) 1.00 (0.32–3.10) 1.00 (0.06–15.99) 0.33 (0.09–1.23)
Holly 1.11 (0.57–2.18) 0.78 (0.57–1.05) 2.01 (0.88–4.55) 1.07 (0.81–1.43)
Holman 0.88 (0.32–2.41) 1.18 (0.53–.2.64) 1.00 (0.20–4.95) 1.89 (0.84–4.24)
Kirkpatrick 0.63 (0.11–3.58) 1.08 (0.48–2.42) 0.95 (0.12–7.61) 0.56 (0.56–1.21)
Langholz 0.48 (0.21–1.07) 0.80 (0.51–1.27) 0.40 (0.14–1.15) 0.61 (0.38–0.97)
Østerlind 0.44 (0.15–1.29) 0.94 (0.57–1.56) 2.63 (0.78–8.81) 1.01 (0.66–1.57)
Swerdlow 1.22 (0.25–6.08) 0.46 (0.15–1.41) 2.00 (0.11–34.82) 1.10 (0.44–2.74)
Zanetti 0.57 (0.17–2.00) 1.70 (0.48–6.00) 2.30 (0.17–30.60) 0.51 (0.12–2.21)
pOR (all studies) 0.83 (0.55–1.25) 0.86 (0.69–1.08) 1.40 (0.80–2.46) 0.88 (0.72–1.09)
w
2 heterogeneity w
2=6.81 w
2=4.05 w
2=9.61 w
2=13.92
(P-value) (P=0.56) (P=0.85) (P=0.29) (P=0.08)
pOR (uniform question format)
b 0.94 (0.59–1.50) 0.88 (0.68–1.13) 1.96 (1.02–3.76) 0.94 (0.75–1.19)
pOR (in-person interview)
c 0.84 (0.54–1.29) 0.85 (0.67–1.08) 1.43 (0.79–2.60) 0.91 (0.73–1.13)
pOR (population based studies)
d 0.81 (0.53–1.25) 0.88 (0.69–1.11) 1.39 (0.77–2.49) 0.88 (0.70–1.09)
aAge-adjusted estimates with never use or use less than 1 year as the reference group.
bExcludes the Langholz et al (2000) study that
phrased contraceptive questions differently.
cExcludes the Kirkpatrick et al (1994) study that used a telephone interview.
dPopulation-
based studies are Gallagher et al, 1985; Green and Bain, 1985; Holly et al, 1995; Holman et al, 1984; Kirkpatrick et al, 1994; Langholz et
al, 2000; Østerlind et al, 1988 and Zanetti et al, 1990.
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melanocytic proliferation, and tumour growth have been observed
following oestrogen (and to a lesser extent progesterone) adminis-
tration in experimental laboratory animals (Snell and Bischitz,
1960; Lopez et al, 1978). Another intriguing ﬁnding is that tamox-
ifen, a selective oestrogen receptor modulator used in the treatment
of breast cancer, improved the median survival time of patients
with metastatic melanoma when used with dacarbazine – an effect
largely observed in women (Cocconi et al, 1992). Oestrogen-bind-
ing receptors have been detected in melanomas and benign nevi of
melanoma patients; although they do not appear to be ‘true’
oestrogen receptors (Walker, 1990).
There have been positive ﬁndings in some studies conducted
after we began our collaborative investigation, and hence could
not be included in the present analyses. In the Nurses Health Study
(NHS) and NHS II cohorts that involved postal surveys, an
elevated risk of melanoma was found in relation to current but
not past use of oral contraceptives (Feskanich et al, 1999).
Compared with never users, a relative risk of 3.4 (95% CI=1.7–
7.0) was observed among current oral contraceptive users who
had used them for 10 years or more. However, even in these large
cohorts, the numbers of exposed and unexposed cases were rela-
tively small (six exposed cases in NHS and eight in NHS II).
Two other recent and relatively large case–control studies reported
from Connecticut and Sweden (Westerdahl et al, 1996; Smith et al,
1998) observed no relation between ever use or duration of oral
contraceptive use and risk of melanoma. But, neither of these
studies speciﬁcally examined current vs past use of oral contracep-
tives. Another case–control study restricted to women less than 55
years of age found an elevated risk (OR=1.5; 95% CI=1.0–2.1) in
relation to 5 or more years of oral contraceptive use, among those
who began use 10 or more years before (Beral et al, 1984). While
this study met the eligibility criteria for our analysis, the original
data were no longer available. It seems unlikely that the addition
of the 287 cases and 574 controls from this study, would have
dramatically altered our ﬁndings based on a total of 2391 cases
and 3199 controls.
Several earlier studies did not collect data on potentially
confounding factors such as sun exposure history or pigmentary
characteristics or nevi and thus were excluded from our analysis
(Beral et al, 1977; Adam et al, 1981; Kay, 1981; Ramcharan et al,
1981; Bain et al, 1982; Holly et al, 1983; Helmrich et al, 1984;
Hannaford et al, 1991; Palmer et al, 1992). The results of these
studies vary. In two studies, an increased risk of melanoma was
observed among long-term users who began using oral contracep-
tives 10 or more years ago (Bain et al, 1982; Beral et al, 1984). In a
hospital-based study, Palmer et al (1992) found a modestly elevated
risk among current oral contraceptive users that was not statisti-
cally signiﬁcant. In our data, the one possibly raised risk was
among the subgroup of long-term users, who started taking oral
contraceptive within 10 years of diagnosis. While these ﬁndings
appear consistent with the NHS results (Feskanich et al, 1999),
we found no evidence of an increase risk associated with current
oral contraceptive use (i.e., use within the past 2 years) even
among the subgroup of long-term, current users.
Increased detection among women who used oral contraceptives
is a plausible explanation for any observed association between
melanoma and oral contraceptive use. In our analysis, we found
little effect on our risk estimates when we adjusted for sociodemo-
graphic factors such as level of education that could be related to
screening behaviour. Indeed, we extensively evaluated the impact of
multiple factors on the odds ratios, but none appreciably altered
the results. In conclusion, our pooled epidemiologic data do not
suggest a major role of oral contraceptives on women’s risk of
melanoma.
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Appendix 1 Classiﬁcation of other covariates included in the pooled analysis of women with and without melanoma
Skin reaction
Level of Family history of Number at ﬁrst summer/
Study Eye color Hair color education melanoma of nevi untanned exposure Sun burn/exposure
Elwood et al, 1990 (Self report) (Self report) Not collected Not available (Number of moles Never burn, burn with long (Severe sunburn ever)
blue, brown, blonde, red, light brown, 3 mm or larger on arms) exposure, always burn yes, no
green/grey/hazel black/dark brown 0, 1–4, 5–9, 10+
Gallagher et al, 1985 (Self report) (Comparison to swatches) (Highest qualiﬁcation) Not available Not collected No burn, rarely burn, burn (Recreational sun exposure)
blue, brown blonde, light brown/red grade/high school, if not enough care taken, lowest, middle, highest
green/grey/hazel brown, black college, graduate school usually burn
Green and Bain, 1985 (Self report) (Self report) (Highest qualiﬁcation) (1st degree relative with (Moles on l. arm62) Tan: no burn, burn and peel, (Ever severe burn)
blue, brown, blonde/light brown, grade/high school, melanoma) yes, no 0, a few, 5–10, 410 burn then tan yes, no
green/grey, hazel brown/auburn, red, college/graduate school (Number of years lived in Australia)
black 0–39, 40+
Holly et al, 1985 (Self report) (Self report) (Highest grade completed) (1st degree relative with (Moles 45 mm, whole Tan: no burn, burn: no tan (Sunburns before age 12 years)
blue, green/grey blonde/lt brown, grade/high school, melanoma, includes body, including removed) burn: light tan, burn: severe, moderate, rarely or never
lt brown/hazel, red, brown, black college, graduate school children) yes, no 0, 1–4, 5–9, 10+ moderate tan
brown
Holman et al, 1984 (Self report) (Comparison to Not available (Blood relative with (Raised nevi below axilla Tan: no burn, burn then (Age migrated to Australia)
blue, brown, swatches) melanoma) yes, no on arms) tan, burn: no tan Native, 515, 515
green/grey/ blonde, red, brown 0, 1–4, 5–9, 10+
hazel black
Kirkpatrick et al, 1994 Not collected (Self report) (Highest grade completed) Not available (Number of moles on (Wearing sunscreen) (Sun exposure index: 2–10 years old)
blonde, red, brown grade/high school, arms) tan: no burn, burn then 530, 31–45, 46–92, 492
black technical school/college, 0, 1–4, 5–9, 10+ tan, burn: no tan
graduate school
Langholz et al, 2000 (Interviewer (Self report) (Highest grade completed) (1st degree relative with (Number of moles any Tan: no burn, burn then (Sunburns age 10–23 years)
comparison to blonde, red/auburn, grade/high school, melanoma, includes size on R. arm62) tan, burn: no tan, no tan 0–9, 10–39, 40+
chart) dark brown brown, black college, graduate children) yes, no 0, 1–4, 5–9, 10+ or burn
brown, blue
Østerlind et al, 1988 (Interviewer (Comparison to (Level of education (1st degree relative with (Number of moles 45 mm Tan: no burn, burn then (Severe sunburn before age 15 years)
recorded) blue, swatches), fair/blonde, attained) high school, melanoma, excludes on arms) tan, burn: no tan yes, no
brown, green/gray red, light brown, dark technical school, children) yes, no 0, 1–4, 5–9, 10+
brown/black university
Swerdlow et al, 1986 (Interviewer (Comparison to Not collected (1st degree relative with (Number of moles 47 mm (Skin type with non-Caucausian (Severe sunburns)
recorded) swatches) melanoma) yes, no on arms) set to missing) Tan: no burn, yes, no
blue, brown, blonde, red, brown, 0, 1–4, 5–9, 10+ burn then tan, burn: no tan
green/grey black
Zanetti et al, 1990 (Self report) (Comparison to (Years of study) (1st degree relative with Not collected (Not restricted to ﬁrst (Sunburn in childhood)
blue, green/grey swatches) blonde/fair grade/high school, melanoma) yes, no summer exposure) never, sometimes, often
black/brown red, light brown, black college, graduate school Tan: no burn, burn then (Number of weeks spent at beach)
dark brown tan, burn: no tan never, 1–42, 43+
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